RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Chief Financial Officer RUBRA MEDICAMENTS LTD. - 531099 - Closure of Trading Window
Pursuant to the Company''s Securities Dealing Code, the Trading Window for dealing in the Company''s Equity Shares will remain closed from Friday, April 1, 2022 for all Designated Employees of the Company. The closure is in connection with the declaration of financial results of the Company for the quarter ending March 31, 2022. The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchanges. RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of Notice of Postal Ballot RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Outcome for Outcome Of Board Meeting
This is to inform you that the Board of Directors of the Company at its meeting held on Friday, March 4, 2022, inter alia, has considered and approved the following: A. Addition of new object in the main object of the company subject to approval of members and other statutory approval. B. Approved notice, calling of postal ballot for: I. Change in name of the Company to new name. II. Addition of new object in the main object of the company. C. The e-voting period begins on Saturday March 5, 2022 at 10.00 a.m. and ends on Monday, April 4, 2022 at 5.00 p.m. During this period, shareholders of the Company holding shares as on the cut-off date i.e. February 25, 2022, may cast their vote electronically. (Copy of Postal Ballot notice Enclosed) RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Is Scheduled On 04/03/2022
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/03/2022 ,inter alia, to consider and approve Addition of new object in the main object of the company subject to approval of members and other statutory approval. RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of Unaudited Financial Results for the quarter and Nine Month ended December 31, 2021 RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Outcome for Outcome Of Board Meeting
This is to inform you that the Board of Directors of the Company at its meeting held on Friday, February 11, 2022, inter alia, has considered and approved the following: A. Unaudited Standalone Financial Results along with Limited review report for the quarter ended December 31, 2021 B. Change in name of the Company to new name subject to approval of the members of the Company and other statutory authorities and calling of Members meeting. RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Board Meeting Of The Directors Of The Company Is Scheduled To Be Held On Friday, February 11, 2022
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 ,inter alia, to consider and approve This is to inform you that a Board Meeting of the Directors of the Company is scheduled to be held on Friday, February 11, 2022 to discuss and approve the following: 1. Standalone unaudited Financial Result along with limited review report for the Quarter ended December 31, 2021. 2. Recommendation for change in name of the Company to new name subject to approval of the members of the Company and other statutory authorities. RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended December 31, 2021
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Managing Director / Whole Time Director